Physician profile
Jian Wei
NPI 1710975248
$4,373.76
in general payments reported to CMS, 2019-2025
26 companies · $656 in 2025
The $656 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $835 · 2021: $951 · 2022: $577 · 2023: $627 · 2024: $295 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $631.51 | 2021-2025 | Ubrelvy |
| Novo Nordisk INC | $508.78 | 2020-2025 | Ozempic, Rybelsus |
| Merz North America, INC. | $502.84 | 2022-2023 | Xeomin |
| Astrazeneca Pharmaceuticals LP | $482.14 | 2021-2025 | Airsupra, Farxiga |
| Amgen INC. | $340.46 | 2019-2025 | Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $311.04 | 2023-2025 | Caplyta |
| Lilly USA, LLC | $277.74 | 2019-2025 | Mounjaro |
| Allergan, INC. | $255.67 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $190.91 | 2022 | |
| Sanofi-Aventis U.S. LLC | $144.29 | 2020-2025 | |
| Glaxosmithkline, LLC. | $131.04 | 2020-2025 | Shingrix, Trelegy Ellipta |
| Pfizer INC. | $122.51 | 2019-2025 | |
| Redhill Biopharma INC. | $102.52 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $66.03 | 2020-2021 | |
| Insulet Corporation | $41.38 | 2025 | Omnipod |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $41.31 | 2020 | |
| Merck Sharp & Dohme LLC | $40.52 | 2019-2020 | |
| Exact Sciences Corporation | $39.25 | 2024-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $32.93 | 2024-2025 | |
| Abbott Laboratories | $17.86 | 2024 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $17.37 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.69 | 2025 | Jardiance |
| Dexcom, INC. | $15.56 | 2021 | |
| Phadia US INC. | $15.07 | 2020 | |
| Genentech USA, INC. | $15.00 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $14.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jian Wei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.